Moleculin Biotech, Inc. Completes Initial Public Offering

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Moleculin Biotech, Inc. Completes Initial Public Offering

NEW YORK, NY and HOUSTON, TX --(Marketwired - June 02, 2016) - Moleculin Biotech, Inc. ( NASDAQ : MBRX ) ("Moleculin" or the "Company") today announced that it closed an initial public offering ("IPO" and or the "Offering") of 1,540,026 common shares for gross proceeds of $9,240,156. The IPO was priced at $6.00 per share, the upper end of the previously-filed $5.00 to $6.00 pricing range. Moleculin's common shares will start to quote at 9:45 AM ET and scheduled to begin trading on NASDAQ Capital Market on or about 10:00 AM ET, under the symbol "MBRX."

The Company plans to use the net proceeds of the offering to commence a further Phase II clinical trial for Annamycin, an anthracycline for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML. Other uses of the MBRX IPO funding include license maintenance and IP prosecution costs, research, and general working capital purposes.

Bonwick Capital Partners, LLC, acted as Lead Bookrunner and Lead Underwriter, and Network 1 Financial Securities, Inc. acted as Co-Underwriter for the Offering.

Moleculin's registration statement relating to the Offering has been filed with, and declared effective by, the United States Securities and Exchange Commission (SEC). This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

The Offering of the securities is made only by means of a prospectus forming a part of the effective registration statement. A copy of the prospectus relating to the Offering may be obtained by contacting Bonwick Capital Partners, LLC, 40 West 57th Street, 28th Floor, New York, New York 10019, Attention: Daniel McClory, Managing Director, Investment Banking or email  dan.mcclory@bonwickcapital.com or by calling (949) 502-4408

Moleculin also announced today the launch of its investor website at  www.moleculin.com . Investors may visit this website for information about the Company, its SEC filings, press releases and other information of interest to current and potential investors. The investor website is not a part of the IPO prospectus.

About Moleculin Biotech, Inc. Moleculin Biotech, Inc. is a preclinical and clinical-stage pharmaceutical company focused on the development of anti-cancer drug candidates, many of which are based on discoveries made at M.D. Anderson Cancer Center. Our lead product candidate is Annamycin, a Phase II clinical stage anthracycline for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML. We also have two active pre-clinical small molecule portfolios, one of which is focused on the modulation of hard-to-target tumor cell signaling mechanisms and the recruitment of the patient's own immune system. The other portfolio targets the metabolism of tumors.

For more information about the offering, please visit  http://www.moleculin.com  

Forward-Looking Statements: Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. These statements relate to future events, future expectations, plans and prospects. Although Moleculin Biotech believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Moleculin Biotech has attempted to identify forward-looking statements by terminology including ''believes,'' ''estimates,'' ''anticipates,'' ''expects,'' ''plans,'' ''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,'' ''might,'' ''will,'' ''should,'' ''approximately'' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under the heading "Risk Factors" in our Registration Statement on Form S-1 originally filed with the Securities and Exchange Commission on February 1, 2016, as amended (Registration No. 333-209323). Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

Contacts: Walter Klemp Chairman Moleculin Biotech Inc. wklemp@moleculin.com   PCG Advisory Investors:  Kirin M. Smith Chief Operating Officer D: 646.863.6519 Media: Sean Leous sleous@pcgadvisory.com Chief Communications Officer D: 646.893.8998 PCGAdvisory.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

RBC Grabs Top Honors for Sustainable Investing Leadership

Updated Category News Views 70

A New Feather in RBC's Cap RBC Wealth Management has racked up more accolades, crowned as the Best Private Bank in Canada and celebrated for its prowess in impact and sustainable investing on the global stage. These distinctions flew in courtesy of the PWM Global Private Banking Awards—a heavyweight recognition in the wealth management world. Award Winning Strategy in...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 279

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading
Parallels Desktop Tops 2026 Picks for Windows on Mac

Updated Category News Views 59

Diving into the Cross-Platform Conundrum Now, I've been in the trenches long enough to know that when companies start relying on Mac computers but can't ditch their essential Windows apps, they're bound to hit a digital brick wall. Picture this—accounting, enterprise management, all that jazz that still needs Windows to function. For those jumping between these two...

Continue Reading
Net Zero Efforts to Cost Europe €60B Annually by 2050

Updated Category News Views 100

Hefty Prices Loom Over Net Zero Commitments Well, strap in for a wallet buster, folks. Europe's largest players are staring down the barrel of a colossal €60 billion annual bill to clean up their carbon mess by 2050. That's the ticker in Senken's latest report, 'Pace of Change 2026.' Talks like these remind me there's no such thing as a free lunch, especially when...

Continue Reading
Stark Future Amasses €150M, Revving Up Electric Bike Dominance

Updated Category News Views 115

Well, if you've been keeping your eye on electric vehicles, this is a story that might raise those eyebrows. Stark Future, a name perhaps not buzzing on every street just yet, has gone and done it—snagged over €150 million in fresh capital. Breaking Barriers with Record-breaking Numbers Stark Future didn't just make a ripple; they caused a tsunami. This buzzing...

Continue Reading
Trades Workforce Shortage Costs Wallop U.S. Economy

Updated Category News Views 36

The Forgotten Backbone of America Don't sleep on this: America's got itself a trade worker crisis, and it's not just a numerical hiccup. We’re down nearly 1.9 million skilled trades workers, and that's a gut punch to the economy—a hefty $1.2 billion a day in GDP loss. These are the folks who keep the wheels greased, the lights on, and the goods flowing. Without them,...

Continue Reading
Gayatri Pariwar Celebrates 100 Years with Massive Yoga Event

Updated Category News Views 72

An Impressive Centenary for Gayatri Pariwar Sometimes, you get hit by a wave so big you can't ignore it, and Gayatri Pariwar's centennial festival in New Delhi was one such tsunami. Picture this: countless souls gathered to mark a hundred years of spiritual and social reform, not just with chants and talks, but through an awe-inspiring mass yoga event. In my decades...

Continue Reading
Palatin's Game-Changer: MC4R Agonist Hits the Stage

Updated Category News Views 62

Breaking New Ground in Obesity Treatment Palatin Technologies is stepping into the spotlight with some heavy ammunition in the fight against obesity. The company has just unveiled impressive preclinical data about their next-generation melanocortin-4 receptor (MC4R) agonists at the ObesityWeek® 2026 conference. This isn’t just your run-of-the-mill corporate...

Continue Reading
Dar Global Expands Jeddah Portfolio with $267M Project

Updated Category News Views 120

Dar Global's Big Jeddah Move: A $267M Bet Alright, let's dive into what Dar Global's been up to in Saudi Arabia. They've just announced a whopping SAR 1 billion development project in Jeddah, bringing an international luxury brand to the city with an exclusive co-branded residential concept. Now that's something to chew on for any investor eyeing the Middle East's real...

Continue Reading
Ozelle Unveils AI-Powered Hematology Tool at MEDICA 2026

Updated Category News Views 116

Pioneering a New Era in Hematology In the fast-paced world of blood analysis, standing still means being left in the dust. Ozelle, with its AI-powered innovative tool, is making waves at MEDICA 2026 in Düsseldorf. Meet O-Cyte 1, an automated hematology analyzer that's merging high-resolution cell imaging with routine CBC (Complete Blood Count) testing. Sounds like...

Continue Reading

Top 5 Most Recently Viewed Articles

Global Smart Waste Management Market Growth Insights

Updated Category News Views 124

Overview of the Smart Waste Management Market In recent years, the smart waste management market has garnered substantial attention, projected to transition from $2.2 billion in valuation to an impressive $8.3 billion. This surge reflects a remarkable compound annual growth rate (CAGR) of 15.6% from 2024 to 2032. The driving force behind this growth stems from increasing...

Continue Reading
Exploring the Collaborative Spirit at the China-US Event

Updated Category News Views 150

Celebrating Cultural Connections The recent 'My China Album' event highlighted the importance of cultural exchanges between the United States and China, focusing on the shared journeys and experiences of citizens from both nations. Strengthening Relations through Understanding During this special occasion, the ambassador emphasized the collaborative spirit that can propel...

Continue Reading
Exciting New Active Adult Community Launches in Central Oregon

Updated Category News Views 143

Welcoming Active Adults to Dry Canyon Introducing Dry Canyon, an extraordinary gated community designed specifically for those aged 55 and better. This remarkable development offers active adults a perfect blend of resort-style living and scenic beauty, all nestled in the heart of Central Oregon. As part of this celebration, Lennar, a well-respected name among...

Continue Reading
XTI Aerospace Announces Upcoming Town Hall for Stakeholders

Updated Category News Views 153

XTI Aerospace Invites Stakeholders to Upcoming Town Hall Updates on Tri-Fan 600, Valkyrie AI and Vanguard Platform ENGLEWOOD, Colo. – XTI Aerospace, Inc. (NASDAQ: XTIA) is at the forefront of advancing vertical flight technologies. The company is making exciting progress with its next-generation vertical takeoff and landing (VTOL) aircraft, the TriFan 600. XTI Aerospace...

Continue Reading
Big Lots Launches Discounts and Donations for Vets in November

Updated Category News Views 47

Big Lots Supports Veterans and Active Military with November Campaigns Every November, Big Lots makes a concerted effort to give back to veterans and active military members. This initiative is a part of their commitment to recognizing the sacrifices made by those who serve our country. Highlighting their respect for military service, Big Lots introduces various discounts...

Continue Reading